Deutsche Bank AG Invests $1.81 Million in Palvella Therapeutics, Inc. $PVLA

Key Points

• Deutsche Bank acquired 11,838 Palvella Therapeutics shares worth approximately $1.81 million, while institutional investors collectively own 40.11% of the company.
• COO Kathleen Goin sold 4,302 shares for about $654,807 under a pre-arranged Rule 10b5-1 plan, reducing her position by 66.64%; insiders still own 17.20% of the stock.
• PVLA recently traded near $149.97 after reporting a quarterly loss of $1.52 per share, missing estimates, while analysts maintain a consensus “Buy” rating with an average price target of $209.14.

Deutsche Bank AG bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 11,838 shares of the company's stock, valued at approximately $1,809,000. Deutsche Bank AG owned 0.08% of Palvella Therapeutics as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in shares of Palvella Therapeutics in the second quarter worth about $4,674,000. State of Wyoming bought a new position in shares of Palvella Therapeutics during the 2nd quarter valued at approximately $134,000. Avidity Partners Management LP raised its stake in Palvella Therapeutics by 262.7% during the 1st quarter. Avidity Partners Management LP now owns 70,000 shares of the company's stock worth $8,726,000 after acquiring an additional 50,700 shares during the period. Arete Wealth Advisors LLC bought a new position in shares of Palvella Therapeutics in the first quarter worth approximately $2,178,000. Finally, Bank of America Corp DE boosted its position in shares of Palvella Therapeutics by 25.4% in the first quarter. Bank of America Corp DE now owns 37,972 shares of the company's stock worth $4,733,000 after purchasing an additional 7,700 shares during the period. Institutional investors own 40.11% of the company's stock.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total value of $654,807.42. Following the sale, the chief operating officer owned 2,154 shares of the company's stock, valued at $327,860.34. The trade was a 66.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Palvella Therapeutics Stock Down 0.2%

Shares of PVLA stock opened at $149.97 on Friday. The company's fifty day simple moving average is $146.01 and its two-hundred day simple moving average is $126.90. Palvella Therapeutics, Inc. has a 52 week low of $49.81 and a 52 week high of $161.38. The stock has a market cap of $2.16 billion, a P/E ratio of -31.05 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating and set a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Stephens reissued an "overweight" rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Chardan Capital upgraded Palvella Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $209.14.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source